251 related articles for article (PubMed ID: 22378683)
1. A murine model of Cryptococcus gattii meningoencephalitis.
Thompson GR; Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Graybill JR; Patterson TF
J Antimicrob Chemother; 2012 Jun; 67(6):1432-8. PubMed ID: 22378683
[TBL] [Abstract][Full Text] [Related]
2. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model.
Ngamskulrungroj P; Chang Y; Sionov E; Kwon-Chung KJ
mBio; 2012; 3(3):. PubMed ID: 22570277
[TBL] [Abstract][Full Text] [Related]
3. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA
Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215
[TBL] [Abstract][Full Text] [Related]
4. Intraspecies variation in the efficacy of adjunctive recombinant interferon-γ therapy against cryptococcal meningoencephalitis in mice.
Ikeda-Dantsuji Y; Nakamura S; Ohno H; Inukai T; Nagi M; Ueno K; Umeyama T; Kinjo Y; Yamagoe S; Shibuya K; Miyazaki Y
Med Mycol; 2018 Apr; 56(3):382-386. PubMed ID: 28992282
[TBL] [Abstract][Full Text] [Related]
5. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Sorrell TC; Patterson TF
Antimicrob Agents Chemother; 2013 Feb; 57(2):745-50. PubMed ID: 23165465
[TBL] [Abstract][Full Text] [Related]
6. Histopathological study of murine pulmonary cryptococcosis induced by Cryptococcus gattii and Cryptococcus neoformans.
Okubo Y; Wakayama M; Ohno H; Yamamoto S; Tochigi N; Tanabe K; Kaneko Y; Yamagoe S; Umeyama T; Shinozaki M; Nemoto T; Nakayama H; Sasai D; Ishiwatari T; Shimodaira K; Yamamoto Y; Kamei K; Miyazaki Y; Shibuya K
Jpn J Infect Dis; 2013; 66(3):216-21. PubMed ID: 23698482
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of Cryptococcus Meningoencephalitis].
Miyazato A
Med Mycol J; 2016; 57(1):J27-32. PubMed ID: 26936349
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
9. Genetic and pathological characteristics of Cryptococcus gattii and Cryptococcus neoformans var. neoformans from meningoencephalitis in autochthonous goats and mouflons, Sardinia, Italy.
Maestrale C; Masia M; Pintus D; Lollai S; Kozel TR; Gates-Hollingsworth MA; Cancedda MG; Cabras P; Pirino S; D'Ascenzo V; Ligios C
Vet Microbiol; 2015 Jun; 177(3-4):409-13. PubMed ID: 25840469
[TBL] [Abstract][Full Text] [Related]
10. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
11. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
12. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
13. Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays.
Treviño-Rangel Rde J; Villanueva-Lozano H; Hernández-Rodríguez P; Martínez-Reséndez MF; García-Juárez J; Rodríguez-Rocha H; González GM
Med Mycol; 2016 Mar; 54(3):280-6. PubMed ID: 26705833
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with Recombinant
Specht CA; Lee CK; Huang H; Hester MM; Liu J; Luckie BA; Torres Santana MA; Mirza Z; Khoshkenar P; Abraham A; Shen ZT; Lodge JK; Akalin A; Homan J; Ostroff GR; Levitz SM
mBio; 2017 Nov; 8(6):. PubMed ID: 29184017
[TBL] [Abstract][Full Text] [Related]
15. Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene.
Leongson K; Cousineau-Côté V; Goupil M; Aumont F; Sénéchal S; Gaboury L; Jolicoeur P; Kronstad JW; de Repentigny L
Infect Immun; 2013 Apr; 81(4):1100-13. PubMed ID: 23340313
[TBL] [Abstract][Full Text] [Related]
16. Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Thailand display diverse phenotypic interactions with macrophages.
Hansakon A; Mutthakalin P; Ngamskulrungroj P; Chayakulkeeree M; Angkasekwinai P
Virulence; 2019 Dec; 10(1):26-36. PubMed ID: 30520685
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological, Clinical and Outcome Aspects of Patients with Cryptococcosis Caused by Cryptococcus gattii from a Non-endemic Area of Brazil.
Damasceno-Escoura AH; de Souza ML; de Oliveira Nunes F; Pardi TC; Gazotto FC; Florentino DH; Mora DJ; Silva-Vergara ML
Mycopathologia; 2019 Feb; 184(1):65-71. PubMed ID: 30415450
[TBL] [Abstract][Full Text] [Related]
18. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
19. Management of Cryptococcus gattii meningoencephalitis.
Franco-Paredes C; Womack T; Bohlmeyer T; Sellers B; Hays A; Patel K; Lizarazo J; Lockhart SR; Siddiqui W; Marr KA
Lancet Infect Dis; 2015 Mar; 15(3):348-55. PubMed ID: 25467646
[TBL] [Abstract][Full Text] [Related]
20. Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice.
Capilla J; Maffei CM; Clemons KV; Sobel RA; Stevens DA
Med Mycol; 2006 Nov; 44(7):601-10. PubMed ID: 17071553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
